Latest Revenue Guidance News

3P Learning forecasts steady revenue for FY25 but anticipates a significant 20% uplift in underlying EBITDA and a stronger net cash position, driven by strategic product expansions.

Duratec Limited has lowered its FY25 revenue and EBITDA guidance due to project delays and weather disruptions but remains optimistic about a robust pipeline and growth prospects in FY26.

SKS Technologies has delivered a robust first half in 2025, showcasing strong revenue growth and a burgeoning project pipeline, underpinned by zero debt and strategic expansion in data centres and traditional electrical services.

AVITA Medical reported a robust 67% increase in first quarter 2025 revenue, driven by new product launches and a strategic commercial overhaul, while reaffirming its full-year growth and profitability targets.

Chrysos Corporation reported a 25% year-on-year revenue increase in Q3 FY25, driven by strong growth in sample volumes and expanded deployment of its PhotonAssay technology across key mining regions.

Motio Limited has upgraded its FY25 financial guidance following robust trading after the April period, raising revenue and cash EBITDA targets while maintaining a solid cash position.

DXN Limited reported a modest 2% revenue increase to $2.5 million in Q3 FY25, launched its Data Centre as a Service division with a $3.6 million initial contract, and progressed a key acquisition valued at $10 million, positioning itself for growth despite some project delays.

Genesis Resources has completed its acquisition of full ownership of the Plavica JV in North Macedonia and is progressing environmental studies and exploration planning for multiple Australian tenements ahead of 2025 drilling campaigns.

Microba Life Sciences reported robust Q3 FY25 growth in its microbiome diagnostic tests, led by MetaXplore and MetaPanel, while advancing its therapeutics pipeline and projecting strong full-year revenue growth.

Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.

Fluence Corporation reported a robust Q1 2025 with revenue surging 64.5% year-over-year, driven by the Ivory Coast Addendum project, while EBITDA turned positive for the first time in over a year. The company maintains its full-year guidance despite tariff uncertainties.

Fluence Corporation Limited reported a robust 64.5% revenue increase in Q1 2025, driven by a strategic pivot to higher-margin Smart Product Solutions and recurring revenue streams, while maintaining its full-year guidance.